Method to Inhibit Toxic Pathways Activated in Genetic ALS/FTD
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)
Modality
Peptide
Mechanism
toxic pathway peptide inhibitor
Target
—
rNPV Envelope
Low
-$34.4M
costs +25% · peak −25%
Base
-$26.0M
cumulative PoS 1.2%
High
-$17.6M
costs −25% · peak +25%
Costs follow a CNS peptide/small-molecule rare-neurodegeneration program with biomarker-enriched C9ORF72 enrollment. PoS is heavily discounted for ALS/FTD endpoint risk, BBB/delivery uncertainty, and the patent's modality breadth rather than a single optimized clinical candidate.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.80
Modality fit · 30%
0.31
Whitespace · 30%
0.50
Composite 0.564 — composite-score rank #50 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#17) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
PTPsigma inhibitor / ISP-DJ001 approach for C9ORF72 ALS/FTD
The direct patent mechanism: inhibiting protein tyrosine phosphatase sigma pathways to reduce neuronal death, inflammation, and degeneration driven by arginine-rich dipeptide repeat toxicity.
Criteria 1: exact patent mechanism; still preclinical and modality-mixed.
TPN-101 - C9ORF72 ALS/FTD clinical-stage comparator
Same genetic ALS/FTD subtype clinical comparator, though it targets retrotransposon/reverse-transcriptase biology rather than PTPsigma.
Criteria 2 and 3: same genetically defined ALS/FTD population and clinical-development context; different mechanism.
C9ORF72 dipeptide-repeat toxicity literature
Mechanism anchor for the target population: C9ORF72 repeat expansion causes RNA foci and dipeptide-repeat proteins including arginine-rich DPRs.
Criteria 1: same disease biology and toxic-protein mechanism.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $10.0M | 24 mo | 36.0% | [0] [1] |
| Phase I | $35.0M | 18 mo | 56.0% | [0] [1] [3] |
| Phase II | $95.0M | 30 mo | 20.0% | [1] [2] [3] |
| Phase III | $190.0M | 42 mo | 36.0% | [2] [3] |
| NDA/BLA Review | $12.0M | 12 mo | 82.0% | [2] |
Multiplier handling: Eligible multipliers (genetic_subtype, serious_unmet_need) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$350.0M peak · WACC 15.0%
Peak revenue. A disease-modifying C9ORF72 ALS/FTD therapy could command rare-neurodegeneration pricing, but the addressable population is a subset and clinical validation is absent. The $350M peak assumes a genetically selected C9ORF72 program, not all ALS/FTD.
WACC. Genetic subtype focus helps, but ALS/FTD clinical translation, CNS delivery, and endpoint risk keep the discount rate high.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$26.0M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$110.2M
P25
-$36.0M
P50 (median)
-$11.1M
P75
-$6.2M
P95
-$3.3M
Prob ≥ 0
0.8%
Evidence register
4 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU asset is ALS/FTD PTPsigma inhibitor approach with BBB/subcutaneous claim cmo_findings.asset_class_reality | Method to Inhibit Toxic Pathways Activated in Genetic ALS/FTD regulatory | 2024-11-26 | high |
Patent mechanism identifies PTPsigma inhibitors and C9ORF72 DPR toxicity comparators[0] | WO2024229355A1 - Methods for decreasing neuronal death, inflammation, and degeneration regulatory | 2024-11-07 | high |
C9ORF72 DPR disease-biology anchor comparators[2] | The Role of Dipeptide Repeats in C9ORF72-Related ALS-FTD peer_review | 2017-02-01 | high |
C9ORF72 ALS/FTD clinical comparator comparators[1] | TPN-101 in C9ORF72 ALS/FTD trial record trial_disclosure | 2025-01-01 | high |
Thesis
Why this asset earns its rank
This is a therapeutic concept, but the mechanism is narrower and more specific than the metadata's target=None suggests. The patent points to PTPsigma inhibition - including ISP or DJ001-like approaches - to reduce neuronal death, inflammation, and degeneration driven by arginine-rich dipeptide-repeat toxicity in C9ORF72 ALS/FTD. The BBB-penetrant peptide claim is important but still preclinical and must be proven with exposure, target engagement, and disease biomarkers.
Comparator economics are rare-neurodegeneration rather than broad ALS. TPN-101 anchors the idea that C9ORF72 ALS/FTD can be developed as a genetically defined clinical population, while C9ORF72 DPR literature anchors the toxic-protein mechanism. The engine result is -$34.4M to -$17.6M, with a base rNPV of -$26.0M and cumulative PoS of 1.2%; that supports a partnership_candidate archetype if the program stays genetically selected and biomarker-driven rather than claiming all ALS/FTD.
Verdict: a credible but very high-risk CNS asset. It earns its rank through severe unmet need and a newly clarified mechanism, but a CMO would ask first for human-relevant CNS exposure, PTPsigma target engagement, and a C9ORF72-specific clinical endpoint strategy.
Key risks
Asset-specific, not generic biotech risks
- Mechanism specificity risk: the JHU page is vague, and the patent mechanism must be framed specifically as PTPsigma inhibition for C9ORF72 DPR toxicity rather than generic ALS/FTD rescue.
- CNS delivery risk: subcutaneous BBB penetration is a core claim that needs rigorous PK, brain exposure, and target-engagement evidence.
- ALS/FTD clinical graveyard: even genetically defined ALS programs face noisy progression endpoints and high failure rates.
- Population-size risk: the credible launch population is C9ORF72 ALS/FTD, not all ALS and all FTD.